Biogen to acquire Nightstar Therapeutics in US$ 800 million cash deal

By PharmaCompass

2019-03-07

Impressions: 158 Article

Earlier this week, Biogen said it will acquire Nightstar Therapeutics for US$ 800 million in cash, as “the company looks to tap into a potentially lucrative gene therapy market.”

London-based gene therapy company Nightstar is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. Nightstar’s lead candidate–NSR-REP1–is currently in Phase III development for choroideremia, a progressive vision loss condition mostly affecting men.

However, Biogen will only be acquiring the technical and clinical expertise of Nightstar. It won't be taking on the manufacturing capabilities with its proposed acquisition. Interestingly, the deal comes just a week after Roche announced its plans to acquire Spark Therapeutics for US$ 4.8 billion in an all-cash transaction.

Spark Therapeutics is currently leading in the gene therapies for inherited retinal diseases space with its breakthrough approval of Luxturna both in the US and Europe.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass